APO Research
Talk to an analyst

APO RESEARCH · REPORT

Manmade Version of Somatostatin

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Manmade Version of Somatostatin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025197 pages

Choose your research edition.

Industry ResearchManmade Version of Somatostatin Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Manmade Version of Somatostatin Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Manmade Version of Somatostatin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Manmade Version of Somatostatin Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Manmade Version of Somatostatin Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Manmade Version of Somatostatin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Manmade Version of Somatostatin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Manmade Version of Somatostatin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Manmade Version of Somatostatin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Manmade Version of Somatostatin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Manmade Version of Somatostatin include Advanz Pharma, Chiesi Farmaceutici S.p.A, Cipla, Fresenius Kabi, Gland Pharma, Heritage Pharmaceuticals, Ipsen, Mylan and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Manmade Version of Somatostatin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Manmade Version of Somatostatin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Manmade Version of Somatostatin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Manmade Version of Somatostatin market size, projected growth trends, production technologies, key applications, and end-use industries.

Manmade Version of Somatostatin Segment by Company

Advanz Pharma

Chiesi Farmaceutici S.p.A

Cipla

Fresenius Kabi

Gland Pharma

Heritage Pharmaceuticals

Ipsen

Mylan

Novartis

Recordati Rare Diseases

Sagent Pharmaceuticals

Sun Pharmaceutical

Teva

West-Ward Pharmaceuticals

Chengdu Tiantaishan pharmaceutical

Hainan Shuangcheng Pharmaceuticals

Hybio Pharmaceutical

Sihuan Pharmaceutical

Suzhou Tianma Pharmaceutical

Manmade Version of Somatostatin Segment by Type

Pasireotide

Lanreotide

Octreotide

Other

Manmade Version of Somatostatin Segment by Application

Cushing Syndrome

Neuroendocrine Tumors

Acromegaly

Other

Manmade Version of Somatostatin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Manmade Version of Somatostatin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Manmade Version of Somatostatin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Manmade Version of Somatostatin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Manmade Version of Somatostatin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Manmade Version of Somatostatin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Manmade Version of Somatostatin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Manmade Version of Somatostatin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Manmade Version of Somatostatin Industry Trends Table 2. Manmade Version of Somatostatin Industry Drivers Table 3. Manmade Version of Somatostatin Industry Opportunities and Challenges Table 4. Manmade Version of Somatostatin Industry Restraints Table 5. Global Manmade Version of Somatostatin Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Manmade Version of Somatostatin Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Manmade Version of Somatostatin Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Manmade Version of Somatostatin Sales Market Share by Manufacturers Table 9. Global Manmade Version of Somatostatin Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Manmade Version of Somatostatin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Manmade Version of Somatostatin Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Manmade Version of Somatostatin Manufacturers, Product Type & Application Table 13. Global Manmade Version of Somatostatin Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Manmade Version of Somatostatin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Pasireotide Table 17. Major Manufacturers of Lanreotide Table 18. Major Manufacturers of Octreotide Table 19. Major Manufacturers of Other Table 20. Global Manmade Version of Somatostatin Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Manmade Version of Somatostatin Sales by Type (2021-2026) & (K Units) Table 22. Global Manmade Version of Somatostatin Sales by Type (2027-2032) & (K Units) Table 23. Global Manmade Version of Somatostatin Sales Market Share by Type (2021-2026) Table 24. Global Manmade Version of Somatostatin Sales Market Share by Type (2027-2032) Table 25. Global Manmade Version of Somatostatin Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Manmade Version of Somatostatin Revenue by Type (2021-2026) & (K Units) Table 27. Global Manmade Version of Somatostatin Revenue by Type (2027-2032) & (K Units) Table 28. Global Manmade Version of Somatostatin Revenue Market Share by Type (2021-2026) Table 29. Global Manmade Version of Somatostatin Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Cushing Syndrome Table 31. Major Manufacturers of Neuroendocrine Tumors Table 32. Major Manufacturers of Acromegaly Table 33. Major Manufacturers of Other Table 34. Global Manmade Version of Somatostatin Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Manmade Version of Somatostatin Sales by Application (2021-2026) & (K Units) Table 36. Global Manmade Version of Somatostatin Sales by Application (2027-2032) & (K Units) Table 37. Global Manmade Version of Somatostatin Sales Market Share by Application (2021-2026) Table 38. Global Manmade Version of Somatostatin Sales Market Share by Application (2027-2032) Table 39. Global Manmade Version of Somatostatin Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Manmade Version of Somatostatin Revenue by Application (2021-2026) & (K Units) Table 41. Global Manmade Version of Somatostatin Revenue by Application (2027-2032) & (K Units) Table 42. Global Manmade Version of Somatostatin Revenue Market Share by Application (2021-2026) Table 43. Global Manmade Version of Somatostatin Revenue Market Share by Application (2027-2032) Table 44. Global Manmade Version of Somatostatin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Manmade Version of Somatostatin Sales by Region (2021-2026) & (K Units) Table 46. Global Manmade Version of Somatostatin Sales Market Share by Region (2021-2026) Table 47. Global Manmade Version of Somatostatin Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Manmade Version of Somatostatin Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Manmade Version of Somatostatin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Manmade Version of Somatostatin Sales by Country (2021-2026) & (K Units) Table 51. North America Manmade Version of Somatostatin Sales by Country (2027-2032) & (K Units) Table 52. Europe Manmade Version of Somatostatin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Manmade Version of Somatostatin Sales by Country (2021-2026) & (K Units) Table 54. Europe Manmade Version of Somatostatin Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Manmade Version of Somatostatin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Manmade Version of Somatostatin Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Manmade Version of Somatostatin Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Manmade Version of Somatostatin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Manmade Version of Somatostatin Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Manmade Version of Somatostatin Sales by Country (2027-2032) & (K Units) Table 61. Global Manmade Version of Somatostatin Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Manmade Version of Somatostatin Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Manmade Version of Somatostatin Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Manmade Version of Somatostatin Revenue Market Share by Region (2021-2026) Table 65. Global Manmade Version of Somatostatin Revenue Market Share by Region (2027-2032) Table 66. Advanz Pharma Company Information Table 67. Advanz Pharma Business Overview Table 68. Advanz Pharma Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Advanz Pharma Manmade Version of Somatostatin Product Portfolio Table 70. Advanz Pharma Recent Development Table 71. Chiesi Farmaceutici S.p.A Company Information Table 72. Chiesi Farmaceutici S.p.A Business Overview Table 73. Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Product Portfolio Table 75. Chiesi Farmaceutici S.p.A Recent Development Table 76. Cipla Company Information Table 77. Cipla Business Overview Table 78. Cipla Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Cipla Manmade Version of Somatostatin Product Portfolio Table 80. Cipla Recent Development Table 81. Fresenius Kabi Company Information Table 82. Fresenius Kabi Business Overview Table 83. Fresenius Kabi Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Fresenius Kabi Manmade Version of Somatostatin Product Portfolio Table 85. Fresenius Kabi Recent Development Table 86. Gland Pharma Company Information Table 87. Gland Pharma Business Overview Table 88. Gland Pharma Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Gland Pharma Manmade Version of Somatostatin Product Portfolio Table 90. Gland Pharma Recent Development Table 91. Heritage Pharmaceuticals Company Information Table 92. Heritage Pharmaceuticals Business Overview Table 93. Heritage Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Heritage Pharmaceuticals Manmade Version of Somatostatin Product Portfolio Table 95. Heritage Pharmaceuticals Recent Development Table 96. Ipsen Company Information Table 97. Ipsen Business Overview Table 98. Ipsen Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Ipsen Manmade Version of Somatostatin Product Portfolio Table 100. Ipsen Recent Development Table 101. Mylan Company Information Table 102. Mylan Business Overview Table 103. Mylan Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Mylan Manmade Version of Somatostatin Product Portfolio Table 105. Mylan Recent Development Table 106. Novartis Company Information Table 107. Novartis Business Overview Table 108. Novartis Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Novartis Manmade Version of Somatostatin Product Portfolio Table 110. Novartis Recent Development Table 111. Recordati Rare Diseases Company Information Table 112. Recordati Rare Diseases Business Overview Table 113. Recordati Rare Diseases Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Recordati Rare Diseases Manmade Version of Somatostatin Product Portfolio Table 115. Recordati Rare Diseases Recent Development Table 116. Sagent Pharmaceuticals Company Information Table 117. Sagent Pharmaceuticals Business Overview Table 118. Sagent Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Sagent Pharmaceuticals Manmade Version of Somatostatin Product Portfolio Table 120. Sagent Pharmaceuticals Recent Development Table 121. Sun Pharmaceutical Company Information Table 122. Sun Pharmaceutical Business Overview Table 123. Sun Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Sun Pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 125. Sun Pharmaceutical Recent Development Table 126. Teva Company Information Table 127. Teva Business Overview Table 128. Teva Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Teva Manmade Version of Somatostatin Product Portfolio Table 130. Teva Recent Development Table 131. West-Ward Pharmaceuticals Company Information Table 132. West-Ward Pharmaceuticals Business Overview Table 133. West-Ward Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. West-Ward Pharmaceuticals Manmade Version of Somatostatin Product Portfolio Table 135. West-Ward Pharmaceuticals Recent Development Table 136. Chengdu Tiantaishan pharmaceutical Company Information Table 137. Chengdu Tiantaishan pharmaceutical Business Overview Table 138. Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 140. Chengdu Tiantaishan pharmaceutical Recent Development Table 141. Hainan Shuangcheng Pharmaceuticals Company Information Table 142. Hainan Shuangcheng Pharmaceuticals Business Overview Table 143. Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Product Portfolio Table 145. Hainan Shuangcheng Pharmaceuticals Recent Development Table 146. Hybio Pharmaceutical Company Information Table 147. Hybio Pharmaceutical Business Overview Table 148. Hybio Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Hybio Pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 150. Hybio Pharmaceutical Recent Development Table 151. Sihuan Pharmaceutical Company Information Table 152. Sihuan Pharmaceutical Business Overview Table 153. Sihuan Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Sihuan Pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 155. Sihuan Pharmaceutical Recent Development Table 156. Suzhou Tianma Pharmaceutical Company Information Table 157. Suzhou Tianma Pharmaceutical Business Overview Table 158. Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 160. Suzhou Tianma Pharmaceutical Recent Development Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. Manmade Version of Somatostatin Distributors List Table 164. Manmade Version of Somatostatin Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Manmade Version of Somatostatin Product Image Figure 2. Global Manmade Version of Somatostatin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Manmade Version of Somatostatin Market Size (2021-2032) & (US$ Million) Figure 4. Global Manmade Version of Somatostatin Sales (2021-2032) & (K Units) Figure 5. Global Manmade Version of Somatostatin Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Manmade Version of Somatostatin Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Pasireotide Image Figure 9. Lanreotide Image Figure 10. Octreotide Image Figure 11. Other Image Figure 12. Global Manmade Version of Somatostatin Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Manmade Version of Somatostatin Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Manmade Version of Somatostatin Sales Market Share by Type (2021-2032) Figure 15. Global Manmade Version of Somatostatin Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Manmade Version of Somatostatin Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Manmade Version of Somatostatin Revenue Market Share by Type (2021-2032) Figure 18. Cushing Syndrome Image Figure 19. Neuroendocrine Tumors Image Figure 20. Acromegaly Image Figure 21. Other Image Figure 22. Global Manmade Version of Somatostatin Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Manmade Version of Somatostatin Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Manmade Version of Somatostatin Sales Market Share by Application (2021-2032) Figure 25. Global Manmade Version of Somatostatin Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Manmade Version of Somatostatin Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Manmade Version of Somatostatin Revenue Market Share by Application (2021-2032) Figure 28. North America Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Manmade Version of Somatostatin Sales Market Share by Country (2021-2032) Figure 30. U.S. Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Manmade Version of Somatostatin Sales Market Share by Country (2021-2032) Figure 35. Germany Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Manmade Version of Somatostatin Sales Market Share by Country (2021-2032) Figure 42. China Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Manmade Version of Somatostatin Sales Market Share by Country (2021-2032) Figure 50. Brazil Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Manmade Version of Somatostatin Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Manmade Version of Somatostatin Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Manmade Version of Somatostatin Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Manmade Version of Somatostatin Revenue (2021-2032) & (US$ Million) Figure 61. North America Manmade Version of Somatostatin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Manmade Version of Somatostatin Revenue (2021-2032) & (US$ Million) Figure 63. Europe Manmade Version of Somatostatin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Manmade Version of Somatostatin Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Manmade Version of Somatostatin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Manmade Version of Somatostatin Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Manmade Version of Somatostatin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Manmade Version of Somatostatin Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Manmade Version of Somatostatin Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Pasireotide
  • Lanreotide
  • Octreotide
  • Other
Applications
  • Cushing Syndrome
  • Neuroendocrine Tumors
  • Acromegaly
  • Other
Companies covered
  • Advanz Pharma
  • Chiesi Farmaceutici S.p.A
  • Cipla
  • Fresenius Kabi
  • Gland Pharma
  • Heritage Pharmaceuticals
  • Ipsen
  • Mylan
  • Novartis
  • Recordati Rare Diseases
  • Sagent Pharmaceuticals
  • Sun Pharmaceutical
  • Teva
  • West-Ward Pharmaceuticals
  • Chengdu Tiantaishan pharmaceutical
  • Hainan Shuangcheng Pharmaceuticals
  • Hybio Pharmaceutical
  • Sihuan Pharmaceutical
  • Suzhou Tianma Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Manmade Version of Somatostatin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Manmade Version of Somatostatin Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Manmade Version of Somatostatin Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Manmade Version of Somatostatin Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Manmade Version of Somatostatin Market Dynamics
  1. 2.1 Manmade Version of Somatostatin Industry Trends
  2. 2.2 Manmade Version of Somatostatin Industry Drivers
  3. 2.3 Manmade Version of Somatostatin Industry Opportunities and Challenges
  4. 2.4 Manmade Version of Somatostatin Industry Restraints
3 Manmade Version of Somatostatin Market by Manufacturers
  1. 3.1 Global Manmade Version of Somatostatin Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Manmade Version of Somatostatin Sales by Manufacturers (2021-2026)
  3. 3.3 Global Manmade Version of Somatostatin Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Manmade Version of Somatostatin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Manmade Version of Somatostatin Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Manmade Version of Somatostatin Manufacturers, Product Type & Application
  7. 3.7 Global Manmade Version of Somatostatin Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Manmade Version of Somatostatin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Manmade Version of Somatostatin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Manmade Version of Somatostatin Tier 1, Tier 2, and Tier 3
4 Manmade Version of Somatostatin Market by Type
  1. 4.1 Manmade Version of Somatostatin Type Introduction
  2. 4.1.1 Pasireotide
  3. 4.1.2 Lanreotide
  4. 4.1.3 Octreotide
  5. 4.1.4 Other
  6. 4.2 Global Manmade Version of Somatostatin Sales by Type
  7. 4.2.1 Global Manmade Version of Somatostatin Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Manmade Version of Somatostatin Sales by Type (2021-2032)
  9. 4.2.3 Global Manmade Version of Somatostatin Sales Market Share by Type (2021-2032)
  10. 4.3 Global Manmade Version of Somatostatin Revenue by Type
  11. 4.3.1 Global Manmade Version of Somatostatin Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Manmade Version of Somatostatin Revenue by Type (2021-2032)
  13. 4.3.3 Global Manmade Version of Somatostatin Revenue Market Share by Type (2021-2032)
5 Manmade Version of Somatostatin Market by Application
  1. 5.1 Manmade Version of Somatostatin Application Introduction
  2. 5.1.1 Cushing Syndrome
  3. 5.1.2 Neuroendocrine Tumors
  4. 5.1.3 Acromegaly
  5. 5.1.4 Other
  6. 5.2 Global Manmade Version of Somatostatin Sales by Application
  7. 5.2.1 Global Manmade Version of Somatostatin Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Manmade Version of Somatostatin Sales by Application (2021-2032)
  9. 5.2.3 Global Manmade Version of Somatostatin Sales Market Share by Application (2021-2032)
  10. 5.3 Global Manmade Version of Somatostatin Revenue by Application
  11. 5.3.1 Global Manmade Version of Somatostatin Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Manmade Version of Somatostatin Revenue by Application (2021-2032)
  13. 5.3.3 Global Manmade Version of Somatostatin Revenue Market Share by Application (2021-2032)
6 Global Manmade Version of Somatostatin Sales by Region
  1. 6.1 Global Manmade Version of Somatostatin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Manmade Version of Somatostatin Sales by Region (2021-2032)
  3. 6.2.1 Global Manmade Version of Somatostatin Sales by Region (2021-2026)
  4. 6.2.2 Global Manmade Version of Somatostatin Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Manmade Version of Somatostatin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Manmade Version of Somatostatin Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Manmade Version of Somatostatin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Manmade Version of Somatostatin Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Manmade Version of Somatostatin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Manmade Version of Somatostatin Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Manmade Version of Somatostatin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Manmade Version of Somatostatin Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Manmade Version of Somatostatin Revenue by Region
  1. 7.1 Global Manmade Version of Somatostatin Revenue by Region
  2. 7.1.1 Global Manmade Version of Somatostatin Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Manmade Version of Somatostatin Revenue by Region (2021-2026)
  4. 7.1.3 Global Manmade Version of Somatostatin Revenue by Region (2027-2032)
  5. 7.1.4 Global Manmade Version of Somatostatin Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Manmade Version of Somatostatin Revenue (2021-2032)
  8. 7.2.2 North America Manmade Version of Somatostatin Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Manmade Version of Somatostatin Revenue (2021-2032)
  11. 7.3.2 Europe Manmade Version of Somatostatin Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Manmade Version of Somatostatin Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Manmade Version of Somatostatin Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Manmade Version of Somatostatin Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Manmade Version of Somatostatin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Advanz Pharma
  2. 8.1.1 Advanz Pharma Company Information
  3. 8.1.2 Advanz Pharma Business Overview
  4. 8.1.3 Advanz Pharma Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Advanz Pharma Manmade Version of Somatostatin Product Portfolio
  6. 8.1.5 Advanz Pharma Recent Developments
  7. 8.2 Chiesi Farmaceutici S.p.A
  8. 8.2.1 Chiesi Farmaceutici S.p.A Company Information
  9. 8.2.2 Chiesi Farmaceutici S.p.A Business Overview
  10. 8.2.3 Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Product Portfolio
  12. 8.2.5 Chiesi Farmaceutici S.p.A Recent Developments
  13. 8.3 Cipla
  14. 8.3.1 Cipla Company Information
  15. 8.3.2 Cipla Business Overview
  16. 8.3.3 Cipla Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cipla Manmade Version of Somatostatin Product Portfolio
  18. 8.3.5 Cipla Recent Developments
  19. 8.4 Fresenius Kabi
  20. 8.4.1 Fresenius Kabi Company Information
  21. 8.4.2 Fresenius Kabi Business Overview
  22. 8.4.3 Fresenius Kabi Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Fresenius Kabi Manmade Version of Somatostatin Product Portfolio
  24. 8.4.5 Fresenius Kabi Recent Developments
  25. 8.5 Gland Pharma
  26. 8.5.1 Gland Pharma Company Information
  27. 8.5.2 Gland Pharma Business Overview
  28. 8.5.3 Gland Pharma Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Gland Pharma Manmade Version of Somatostatin Product Portfolio
  30. 8.5.5 Gland Pharma Recent Developments
  31. 8.6 Heritage Pharmaceuticals
  32. 8.6.1 Heritage Pharmaceuticals Company Information
  33. 8.6.2 Heritage Pharmaceuticals Business Overview
  34. 8.6.3 Heritage Pharmaceuticals Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Heritage Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
  36. 8.6.5 Heritage Pharmaceuticals Recent Developments
  37. 8.7 Ipsen
  38. 8.7.1 Ipsen Company Information
  39. 8.7.2 Ipsen Business Overview
  40. 8.7.3 Ipsen Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ipsen Manmade Version of Somatostatin Product Portfolio
  42. 8.7.5 Ipsen Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mylan Manmade Version of Somatostatin Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Manmade Version of Somatostatin Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Recordati Rare Diseases
  56. 8.10.1 Recordati Rare Diseases Company Information
  57. 8.10.2 Recordati Rare Diseases Business Overview
  58. 8.10.3 Recordati Rare Diseases Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Recordati Rare Diseases Manmade Version of Somatostatin Product Portfolio
  60. 8.10.5 Recordati Rare Diseases Recent Developments
  61. 8.11 Sagent Pharmaceuticals
  62. 8.11.1 Sagent Pharmaceuticals Company Information
  63. 8.11.2 Sagent Pharmaceuticals Business Overview
  64. 8.11.3 Sagent Pharmaceuticals Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sagent Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
  66. 8.11.5 Sagent Pharmaceuticals Recent Developments
  67. 8.12 Sun Pharmaceutical
  68. 8.12.1 Sun Pharmaceutical Company Information
  69. 8.12.2 Sun Pharmaceutical Business Overview
  70. 8.12.3 Sun Pharmaceutical Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sun Pharmaceutical Manmade Version of Somatostatin Product Portfolio
  72. 8.12.5 Sun Pharmaceutical Recent Developments
  73. 8.13 Teva
  74. 8.13.1 Teva Company Information
  75. 8.13.2 Teva Business Overview
  76. 8.13.3 Teva Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Teva Manmade Version of Somatostatin Product Portfolio
  78. 8.13.5 Teva Recent Developments
  79. 8.14 West-Ward Pharmaceuticals
  80. 8.14.1 West-Ward Pharmaceuticals Company Information
  81. 8.14.2 West-Ward Pharmaceuticals Business Overview
  82. 8.14.3 West-Ward Pharmaceuticals Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 West-Ward Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
  84. 8.14.5 West-Ward Pharmaceuticals Recent Developments
  85. 8.15 Chengdu Tiantaishan pharmaceutical
  86. 8.15.1 Chengdu Tiantaishan pharmaceutical Company Information
  87. 8.15.2 Chengdu Tiantaishan pharmaceutical Business Overview
  88. 8.15.3 Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Product Portfolio
  90. 8.15.5 Chengdu Tiantaishan pharmaceutical Recent Developments
  91. 8.16 Hainan Shuangcheng Pharmaceuticals
  92. 8.16.1 Hainan Shuangcheng Pharmaceuticals Company Information
  93. 8.16.2 Hainan Shuangcheng Pharmaceuticals Business Overview
  94. 8.16.3 Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
  96. 8.16.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
  97. 8.17 Hybio Pharmaceutical
  98. 8.17.1 Hybio Pharmaceutical Company Information
  99. 8.17.2 Hybio Pharmaceutical Business Overview
  100. 8.17.3 Hybio Pharmaceutical Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Hybio Pharmaceutical Manmade Version of Somatostatin Product Portfolio
  102. 8.17.5 Hybio Pharmaceutical Recent Developments
  103. 8.18 Sihuan Pharmaceutical
  104. 8.18.1 Sihuan Pharmaceutical Company Information
  105. 8.18.2 Sihuan Pharmaceutical Business Overview
  106. 8.18.3 Sihuan Pharmaceutical Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Sihuan Pharmaceutical Manmade Version of Somatostatin Product Portfolio
  108. 8.18.5 Sihuan Pharmaceutical Recent Developments
  109. 8.19 Suzhou Tianma Pharmaceutical
  110. 8.19.1 Suzhou Tianma Pharmaceutical Company Information
  111. 8.19.2 Suzhou Tianma Pharmaceutical Business Overview
  112. 8.19.3 Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Product Portfolio
  114. 8.19.5 Suzhou Tianma Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Manmade Version of Somatostatin Value Chain Analysis
  2. 9.1.1 Manmade Version of Somatostatin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Manmade Version of Somatostatin Production Mode & Process
  6. 9.2 Manmade Version of Somatostatin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Manmade Version of Somatostatin Distributors
  9. 9.2.3 Manmade Version of Somatostatin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst